Sinopharm Accord reports revenue and profit declines in first nine months

For the nine months ended September 30, 2025, Sinopharm Accord recorded a total revenue of 55.124 bn yuan, a 2.38% year-on-year decrease. Net profit attributable to shareholders of the listed company also fell by 10.18% to 0.957 bn yuan. Basic earnings per share declined by 9.95%, and the weighted average return on net assets decreased by 0.70 percentage points.

The distribution segment saw revenue decline by 0.59% to 40.594 bn yuan, with net profit down 7.32% to 0.723 bn yuan due to increased credit impairment losses. In contrast, the retail segment, represented by Guoda Drugstore, experienced a 7.14% revenue decrease to 15.226 bn yuan, yet its net profit surged by 133.91% to 13 m yuan, driven by procurement optimization and strategic store closures.

Total assets for Sinopharm Accord stood at 5,055,886.26 at the end of the reporting period, an increase of 6.31% from the beginning of the period. Equity attributable to shareholders grew by 4.30% to 1,842,994.62, with net assets per share at 33.11 yuan.